Kenvue Inc. (NYSE:KVUE) Given Average Rating of “Hold” by Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned an average rating of “Hold” from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. Twelve research analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $19.3333.

KVUE has been the topic of several research reports. Argus raised Kenvue to a “hold” rating in a research report on Friday, March 6th. Barclays dropped their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Canaccord Genuity Group increased their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research report on Wednesday, February 18th. Citigroup dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Finally, UBS Group dropped their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 7th.

Kenvue Stock Performance

KVUE stock opened at $17.72 on Wednesday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The firm has a market cap of $34.01 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.34 and a beta of 0.54. Kenvue has a 12-month low of $14.02 and a 12-month high of $22.87. The stock’s 50 day simple moving average is $17.37 and its 200 day simple moving average is $17.48.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business’s revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 EPS. As a group, equities research analysts predict that Kenvue will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a document filed with the SEC, which is available through this link. 1.59% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kenvue

Large investors have recently added to or reduced their stakes in the stock. Cornerstone Planning Group LLC increased its position in Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the period. Physician Wealth Advisors Inc. increased its position in Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Elyxium Wealth LLC acquired a new stake in Kenvue in the fourth quarter worth $26,000. MV Capital Management Inc. acquired a new stake in Kenvue in the fourth quarter worth $28,000. Finally, Reflection Asset Management acquired a new position in shares of Kenvue during the fourth quarter valued at $32,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.